Matching Portfolios

by David Kane and Jeff Enos

January 1, 2006

1   Introduction

"Matching" portfolios is a technique for generating a reasonable benchmark for determining the relative performance of a specific equity portfolio and is based on the work in Ho et al. (2005a). Consider the simplest case of a long-only mutual fund that has returned 10% in the last year. Has the portfolio done well? If the average stock in the universe has gone up 50% then, obviously, the portfolio has done poorly. If, on the other hand, the average stock has gone down 25%, then the portfolio has done remarkably well. In other words, it is impossible to evaluate the performance of a portfolio without considering the hypothetical performance of other possible portfolios. In this case, we are comparing the performance of our portfolio to that of a hypothetical portfolio that is equal-weighted all the stocks in the universe. But, depending on the characteristics of our mutual fund, this may not be a reasonable benchmark. More information on the performance measurement problem and possible solutions can be found in Burns (2004).

Matching portfolios provide a benchmark which matches the characteristics — sector exposures, capitalization biases, position sizes — of the target portfolio. The `portfolio` package provides the `matching` method as a means of computing a matching portfolio. In this article we describe the intuition behind matching in general, frame a real-world problem in which computing a portfolio benchmark is difficult, and show how the matching facility of the portfolio package can be used to solve this problem.

2   Data

To focus ideas, let's examine a specific portfolio formed on December 31, 2004. Assay Research[1] is a forensic accounting that provides "in-depth insight into financial statements, accounting practices and policies, and quality-of-earnings of publicly-traded companies." Assay maintains a "Focus List" of companies for which its concerns are "heightened." Although Assay does not provide buy/sell recommendations, most if its customers would expect the stocks on its Focus List to perform poorly going forward.

---

[1]www.assayresearch.com

On December 31, 2004, there were 33 companies on Assay's Focus List. The list of companies, along with data on a total of 4,000 stocks that were trading at that time, are available as part of the R "portfolio" package.

```
> library(portfolio)

Loading required package: grid
Loading required package: lattice

> data(assay)
> assay[c(1, 10, 100, 1000, 3000, 767), ]

            id symbol                name country currency price      sector
22101 36960410     GE GENERAL ELECTRIC CO    USA      USD    36 Industrials
29780 47816010    JNJ    JOHNSON & JOHNSON    USA      USD    63     Staples
17157 26054310    DOW         DOW CHEMICAL    USA      USD    50   Materials
57743   663710 NCM.AU NEWCREST MINING LTD    AUS      AUD    17   Materials
52459   646862   8584         JACCS CO LTD    JPN      JPY   616  Financials
6930  G3726010   GRMN          GARMIN LTD    USA      USD    61  Technology
      liquidity assay ret.0.3.m ret.0.6.m
22101      2.84 FALSE   -0.0059    -0.021
29780      2.42 FALSE    0.0635     0.078
17157      1.90 FALSE    0.0137    -0.089
57743      0.74 FALSE   -0.0023    -0.115
52459     -0.47 FALSE    0.2138     0.142
6930       1.63  TRUE   -0.2387    -0.297
```

The variables in the data frame are as follows.

- **id** is an identifier for each security, generally a CUSIP for companies traded on US exchanges and a SEDOL for companies traded elsewhere.

- **symbol** is a human-readable identifier that is generally the ticker that the security trades under in its home market; exchange specific information is sometime appended to it. For example, Newcrest Mining trades under the ticker "NCM" in Australia, indicated by the "AU" suffix.

- **name** is the name of the company. We will generally use the terms "company" and "security" interchangeably even though a "company" is a single legal entity which often has several different types of securities associated with it. In this example, we are only examining the single primary equity security for each company.

- **country** is the ISO code for the country in which the security is traded. Note that this is not necessarily the same as the country in which the company is headquartered or incorporated. For example, Garmin (GRMN) is trades in the US but is incorporated in the Cayman Islands.[2]

- **currency** is the ISO code for the currency in which the security trades.

---

[2]http://www.garmin.com

- **price** is the latest closing price for the security as of December 31, 2004. (Not all securities traded on that date.)

- **sector** is the economic sector in which a majority of the company's business takes place. There are 10 sectors in this data including Communications, Cyclicals, Energy, Financials and Technology.

- **liquidity** is a measure of the typical daily dollar volume of trading in the security. We normalized it to be $N(0,1)$..

- **assay** is a TRUE/FALSE indicator of whether or not the security was on the Assay Focus List on December 31, 2004. Thirty three companies were on the list at that time.

- **ret.0.3.m** and **ret.0.6.m** are the three and six month, respectively, returns for each security, including dividends.

There are no missing observations. The universe of 4,000 companies was constructed by including the all the stocks on the Assay Focus list along with other large companies. The universe is restricted to companies that trade on exchanges in developed markets. For example, we include Japan but not South Korea, Austria but not Croatia.

3 An Assay Focus List (AFL) Portfolio

Consider a portfolio formed by taking equal-weighted short positions in each of the Assay Focus List stocks and focusing in the returns for the first three months, through March 31, 2005.

```
> assay$assay.wt <- ifelse(assay$assay, -1, NA)
> p <- new("portfolioBasic", data = assay, id.var = "symbol", in.var = "assay.wt",
+     type = "relative", size = "all", ret.var = "ret.0.3.m")

An object of class "portfolioBasic" with 33 positions

Selected slots:
name: Unnamed portfolio
date: 2006-01-01
in.var: assay.wt
ret.var: ret.0.3.m
type: relative
size: all

> summary(p)

Portfolio: Unnamed portfolio

        count       weight
Long:       0            0
```

```
Short:      33          -1

Top/bottom positions by weight:
     id pct
1  ACXM  -3
2  AFFX  -3
3  ANSI  -3
4  ARTC  -3
5    AV  -3
29  SLE  -3
30  UNA  -3
31 USPI  -3
32 UTSI  -3
33  VCI  -3

> summary(performance(p))

Total return:  7.64 %

Best/Worst performers:
     id weight    ret contrib
18 HOTT -0.030   0.27 -0.0082
21 KOMG -0.030   0.19 -0.0058
2  AFFX -0.030   0.17 -0.0052
26 PDCO -0.030   0.15 -0.0046
12 ELAB -0.030   0.12 -0.0036
24 OPWV -0.030  -0.21  0.0064
17 GRMN -0.030  -0.24  0.0072
3  ANSI -0.030  -0.32  0.0097
5    AV -0.030  -0.32  0.0097
32 UTSI -0.030  -0.51  0.0153
```

This portfolio returns 7.64% because the average Assay stock fell in price by this amount during the first quarter of 2005. Now, making 7% in three months is rarely a bad thing, but whether or not this counts as good performance depends on what the other stocks in the universe did during this time period. After all, instead of paying for access to Assay's Focus List (AFL), we could have just selected 33 stocks randomly and shorted them.

Since the average stock in our universe of 4,000 was up 1.4%, the performance of the AFL portfolio appears quite good. If we consider a reasonable benchmark to be shorting 33 randomly selected stocks from the universe, then the AFL portfolio would have outperformed by 9%.

But is the Assay portfolio similar to the rest of the universe? To some extent, it is. All the securities in the universe are relatively larger capitalization, liquid equities traded on developed market stock exchanges. But the AFL portfolio is also very different since all of its components are US stocks. Is it fair to use a benchmark with international stocks as a comparison for a US-only portfolio like APL? Probably not.

Another major difference between the AFL portfolio and the universe is that the AFL is concentrated in a limited number of sectors.

```
> exposure(p, exp.var = "sector")

sector
         variable long   short exposure
1 Communications    0 -0.091   -0.091
3    Industrials    0 -0.091   -0.091
2      Cyclicals    0 -0.121   -0.121
4        Staples    0 -0.303   -0.303
5     Technology    0 -0.394   -0.394
```

The analysts at Assay do not place companies from sectors like Financials, Energy and Utilities on to their Focus List because they lack the industry knowledge to evaluate the financial statements for such companies. Any benchmark which includes securities from such sectors is inappropriate for judging the skill of Assay. After all, if Energy stocks did very well in the first quarter of 2005, a benchmark short portfolio which included them would do very poorly. Assay would hardly deserve "credit" for this since it is not claiming that stocks in sectors which it does not cover will do well. It makes no predictions about how energy stocks, on average, will do.[3]

Even if we were to eliminate non-US stocks from the universe *and* stocks in sectors that Assay does not cover, we would still be left with a variety of incompatibilities between the AFL portfolio and possible benchmarks. For example, the average Assay stock has a liquidity of over 0.5, more than 1/2 a standard deviation greater than the universe as a whole. The Assay portfolio has almost 40% of its holdings in Technology stocks. The universe as a whole is only 7% Technology. What we need is a benchmark portfolio that looks like, that "matches," the Assay portfolio in terms of variables like country, sector, liquidity and so on but which is otherwise randomly selected from non-Assay stocks in the universe.

4 A Matching Portfolio

The solution to the problem of constructing a benchmark for a portfolio like that derived from the Assay Focus List is to create a "matching" portfolio, a portfolio that is as similar in its characteristics as the target portfolio as possible without being identical to it. For the AFL benchmark, we would like a portfolio with similar country and sector breakdown as well as a similar distribution of liquidity. If the AFL portfolio does much better (because the Assay stocks do very poorly) than this benchmark, we have evidence that Assay has in fact identified companies with significant problems. It isn't just a matter of the AFL doing well relative to the overall universe because, for example, Energy stocks have risen so much and the AFL isn't short any energy stocks.

---

[3]Energy was, in fact, the best performing sector in Q1 2005, with the average stock up over 15%.

4.1   Statistical Intuition

One way to think about the assessment of the AFL is to consider an analogy to a randomized scientific experiment. Recall that a randomized experiment or trial begins by selecting a group of subjects to work with. From this population, a group of subjects is randomly selected and to whom is applied the treatment. The rest of the group receives the control. Since the treatment was applied randomly, any differences in the outcome should be the result of the treatment rather than be caused by systematic differences between the treatment and control groups (Rubin (1974)).

Consider a group of 4000 individuals with a headache. We want to determine if the treatment of "taking an aspirin" relieves the headache better than the control of "taking a placebo." If we only have, say, 33 aspirins to use for the test, we should select 33 people at random from the group of 4000 and give them each an aspirin. The other individuals get the placebo. Afterward, we can see how the treatment group (having taken the aspirin) compares to the control group (who took the placebo). If, for example, the reported headache pain of the treated group is much lower than that of the control group, we might conclude that aspirin works.

Imagine that we have a "treatment" which we believe causes stock prices to fall. We want to test to see if this treatment actually has that effect. The best way to do so is to run a randomized trial. Select, say, 33 stocks at random from the total universe of 4,000 stocks. Apply the treatment to those 33 stocks but not to the other 3,967. If the price of the 33 treated stocks falls more (or rises less) then the prices of the 3,967 control stocks, we might conclude that the treatment works.

The problem arises, for both tests of aspirin and tests of Assay, when we can no longer do random assignment. Imagine that, instead of assigning aspirin/placebo randomly, 33 of the 4,000 people in our group volunteer to take it. The problem is that these 33 might be very different from the others. They might be all men or mostly old or very fat. Unless we somehow "control" for this problem, we will not be able to conclude that the treatment, the aspirin, actually caused the decrease in headache pain. Instead, it could just be that headaches go away more quickly in old, fat men. Instead of comparing our 33 volunteers to everyone else, we need to compare them to a subgroup that "matches" them. If they are mostly male, old and fat, we should select a control group of people who took the placebo that is equally male, old and fat. If aspirin-takers report less pain in this group, then we might reasonably conclude that — at least within this subpart of the population — aspirin works.

The same intuition lies behind the construction of a matching portfolio. We need a portfolio that looks like the AFL portfolio in terms of country, sector and liquidity. If the only difference between the AFL and matching portfolio is that the former consists of stocks that Assay has "heightened" concerns about while the latter consists of similar stocks without such concerns, we may conclude that any differences in their subsequent performance is due to the treatment received. Now, of course, placement on the Focus List does not *cause* a stock

decline in the same way that taking an aspirin causes, by hypothesis, headache pain to decrease. But, mathematically, the set up is the same.

4.2 Making a Match

We want a matching portfolio which is as similar as possible to the Assay Focus List portfolio but which does not include the same stocks. The `matching` method in the `portfolio` package provides this functionality, with a little help from the MatchIt package (Ho et al. (2005b)). Calling this method on a `portfolio` object `p` returns a portfolio with none of the same positions as `p` but whose positions most closely resemble those in `p` along the dimensions specified in the `covariates` argument:

```
> p.m <- matching(p, covariates = c("country", "sector", "liquidity"))

> summary(p.m)

Portfolio: Unnamed portfolio

        count       weight
Long:       0            0
Short:     33           -1

Top/bottom positions by weight:
     id   pct
1  ABGX -3.03
2  ALTR -3.03
3  AVID -3.03
4    BE -3.03
5   BOL -3.03
29 TSRA -3.03
30 TTWO -3.03
31 USTR -3.03
32  WCG -3.03
33  YCC -3.03
```

A quick inspection of the new portfolio's positions confirms that none of the positions of `p.m` appear in `p`.

```
> all(!p.m@weights$id %in% p@weights$id)

[1] TRUE
```

Having created a matching portfolio using country, sector, and liquidity as covariates, we would expect `p.m` and `p` to have similar exposures to these variables. First, all of the positions in `p.m` have country `USA`. This makes sense because all AFL stocks, and thus all stocks in `p`, are US stocks. More interestingly, however, the sector exposures of `p.m` are quite similar to the sector exposures of `p`:

```
> exposure(p.m, exp.var = "sector")

sector
          variable long      short exposure
1 Communications      0 -0.06061 -0.06061
2      Cyclicals      0 -0.09091 -0.09091
3    Industrials      0 -0.12121 -0.12121
4         Staples      0 -0.33333 -0.33333
5     Technology      0 -0.39394 -0.39394
```

The only difference sector-wise between the two portfolios is that `p.m` has one more stock in Staples and one less stock in Communications. Finally, the exposure of `p` to the numeric variable liquidity:

```
> exposure(p, exp.var = "liquidity")

numeric
   variable long  short exposure
1 liquidity    0 -0.541   -0.541
```

is quite close to `p.m`'s exposure to liquidity:

```
> exposure(p.m, exp.var = "liquidity")

numeric
   variable long   short exposure
1 liquidity    0 -0.4894  -0.4894
```

Since we matched using more than one covariate, we shouldn't expect the matching portfolio's exposures to the covariates to be exactly the same as those of the original portfolio. However, given a large enough universe upon which the `matching` method can draw, we expect those exposures to be reasonably close.

4.3   The Match as a Benchmark

Now that we've run `matching` on our AFL portfolio and calculated a match, we can examine how the AFL portfolio performed relative to the match. Recall that the AFL portfolio returned 7.64% during Q1 2005, and that members of our 4000 stock universe were up 1.4% on average during this period. The AFL portfolio, then, outperformed a randomly selected portfolio of 33 stocks from our universe by 9%.

The match, however, performed far better than a randomly selected portfolio:

```
> summary(performance(p.m))

Total return:  4.78 %

Best/Worst performers:
     id   weight    ret   contrib
```

```
7  CMTL -0.03030  0.3853 -0.011675
29 TSRA -0.03030  0.1618 -0.004903
5   BOL -0.03030  0.1392 -0.004219
30 TTWO -0.03030  0.1239 -0.003754
10  ELX -0.03030  0.1188 -0.003599
9  ECLP -0.03030 -0.2423  0.007342
14 IMCL -0.03030 -0.2513  0.007615
19 MTSN -0.03030 -0.2917  0.008840
1  ABGX -0.03030 -0.3230  0.009788
17 LVLT -0.03030 -0.3923  0.011889
```

The match returned 4.78% during Q1 2005, a far better return than the -1.4% of a randomly selected portfolio. If we then use the matching portfolio as the AFL portfolio's benchmark, the AFL portfolio had an excess return of 2.86%. While this excess return is lower than the 9% we would calculate using a randomly selected benchmark, it more accurately reflects the excess return for which Assay should receive "credit".

For example, while the average stock in our universe returned 1.4%, the average US stock returned -3.6%. We could have simply shorted a random collection of 33 US stocks and walked away with 3.6%. Futhermore, stocks in the Technology and Staples sectors on average returned -4.7% and -4.5%, respectively. The matching portfolio, like the AFL portfolio, benefits from having over two-thirds of its positions in these sectors. Finally, stocks with liquidity values close to 0.5, the average liquidity value of AFL stocks, have the same or slightly poorer returns than the average stock in the universe. The AFL portfolio does not perform better or worse than a random portfolio due to its exposure to higher liquidity stocks.

It is clear that the matching portfolio is a better benchmark for the AFL portfolio than a randomly selected portfolio, particularly due to the poor average return of US stocks and stocks in the Technology and Staples sectors relative to the entire universe.

References

Patrick Burns. Performance measurement via random portfolios, 2004. URL http://www.burns-stat.com/pages/Working/perfmeasrandport.pdf.

Daniel Ho, Kosuke Imai, Gary King, and Elizabeth Stuart. Matching as nonparametric preprocessing for parametric causal inference, 2005a. URL http://gking.harvard.edu/files/matchp.pdf.

Daniel Ho, Kosuke Imai, Gary King, and Elizabeth Stuart. *MatchIt: Nonparametric Preprocessing for Parametric Casual Inference*, 2005b. URL http://gking.harvard.edu/matchit. R package version 2.2-5.

Donald B. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66:688–701, 1974.